biostudies-literatureUnknown13(1)Kmak JAProstate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.Case reports in oncology456-461https://www.ebi.ac.uk/biostudies/studies/S-EPMC7204854biostudies-literatureExceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation.PMC7204854Kmak JAKilari DAgarwal NPal SKAli SMHeilmann AMMiller VAHe YRoss JSfalseExceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation.Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.2020-01-01T00:00:00Z2020 Jan-Apr2021-02-20T04:15:08Z2020-05-22T20:07:59ZS-EPMC72048543239901610.1159/000506625